Program
CT204V-CD19 × CD20
A development code.
Its studies are led by AstraZeneca.
Furthest: phase 2, since Nov 6, 20261 company-led study, 1 open or runningNext primary completion: Oct 15, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 2since Nov 6, 2026 | Nov 6, 2026 | Oct 15, 2029phase 2 · NCT07932496 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 6, 2026First study: phase 2 study in RecurrenceFirst studyNCT07932496 · 160 planned
Ahead
- Oct 15, 2029Primary completion: phase 2 study in RecurrenceNCT07932496
TargetBeta
“A Modular, Phase I/II, Open-label, Single-arm, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of CT204V-CD19 × CD20, an In Vivo Lentiviral Vector Gene Therapy Generating Dual Targeting Anti-CD19/CD20 Ch…”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
| Autologous Anti-CD19/CD20 CAR-T Cells KITE-363rule | Gilead Sciences | phase 2 | 3 |
| prizloncabtagene autoleucelrule | AbelZeta | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203rule | avencell-therapeutics-inc | phase 2 | 1 |
| HB2198rule | hinge-bio | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07932496Recurrence | 2 | Not yet recruiting | Oct 15, 2029 | 160 |
How it is read
Names in the registry
- “CT204V-CD19 × CD20”, 1 entry
Codes read as this program: CT204V.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.